Use of the dexamethasone suppression test using DSM-III criteria on an inpatient psychiatric unit

D. L. Evans, Charles Nemeroff

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The authors report here our clinical experience with the DST (dexamethasone suppression test) in a nonresearch setting. In an effort to assess the potential clinical utility of the DST they administered the DST to 21 consecutively admitted patients to the general psychiatry ward who met DSM-III criteria for major depression and to seven patients with depressive symptoms who did not meet criteria for major depression but who met DSM-III criteria (APA, 1980) for other diagnoses ('secondary depression'). The present study confirms and extends previous reports of hypothalamic-pituitary-adrenal axis hyperactivity in a large percentage of depressed patients as evidenced by lack of suppression of serum cortisol levels after orally administered dexamethasone. An abnormal DST was seen in 71% of patients with a DSM-III diagnosis of major depression. This was a significantly higher incidence when compared to patients with depressive symptoms with other DSM-III diagnoses (secondary depression).

Original languageEnglish
Pages (from-to)505-511
Number of pages7
JournalBiological Psychiatry
Volume18
Issue number4
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Diagnostic and Statistical Manual of Mental Disorders
Dexamethasone
Psychiatry
Inpatients
Depression
Patients' Rooms
Hydrocortisone
Incidence
Serum

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Use of the dexamethasone suppression test using DSM-III criteria on an inpatient psychiatric unit. / Evans, D. L.; Nemeroff, Charles.

In: Biological Psychiatry, Vol. 18, No. 4, 01.01.1983, p. 505-511.

Research output: Contribution to journalArticle

@article{c1ddd68c33fc4b4dbd5838a8fb9ef7dd,
title = "Use of the dexamethasone suppression test using DSM-III criteria on an inpatient psychiatric unit",
abstract = "The authors report here our clinical experience with the DST (dexamethasone suppression test) in a nonresearch setting. In an effort to assess the potential clinical utility of the DST they administered the DST to 21 consecutively admitted patients to the general psychiatry ward who met DSM-III criteria for major depression and to seven patients with depressive symptoms who did not meet criteria for major depression but who met DSM-III criteria (APA, 1980) for other diagnoses ('secondary depression'). The present study confirms and extends previous reports of hypothalamic-pituitary-adrenal axis hyperactivity in a large percentage of depressed patients as evidenced by lack of suppression of serum cortisol levels after orally administered dexamethasone. An abnormal DST was seen in 71{\%} of patients with a DSM-III diagnosis of major depression. This was a significantly higher incidence when compared to patients with depressive symptoms with other DSM-III diagnoses (secondary depression).",
author = "Evans, {D. L.} and Charles Nemeroff",
year = "1983",
month = "1",
day = "1",
language = "English",
volume = "18",
pages = "505--511",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Use of the dexamethasone suppression test using DSM-III criteria on an inpatient psychiatric unit

AU - Evans, D. L.

AU - Nemeroff, Charles

PY - 1983/1/1

Y1 - 1983/1/1

N2 - The authors report here our clinical experience with the DST (dexamethasone suppression test) in a nonresearch setting. In an effort to assess the potential clinical utility of the DST they administered the DST to 21 consecutively admitted patients to the general psychiatry ward who met DSM-III criteria for major depression and to seven patients with depressive symptoms who did not meet criteria for major depression but who met DSM-III criteria (APA, 1980) for other diagnoses ('secondary depression'). The present study confirms and extends previous reports of hypothalamic-pituitary-adrenal axis hyperactivity in a large percentage of depressed patients as evidenced by lack of suppression of serum cortisol levels after orally administered dexamethasone. An abnormal DST was seen in 71% of patients with a DSM-III diagnosis of major depression. This was a significantly higher incidence when compared to patients with depressive symptoms with other DSM-III diagnoses (secondary depression).

AB - The authors report here our clinical experience with the DST (dexamethasone suppression test) in a nonresearch setting. In an effort to assess the potential clinical utility of the DST they administered the DST to 21 consecutively admitted patients to the general psychiatry ward who met DSM-III criteria for major depression and to seven patients with depressive symptoms who did not meet criteria for major depression but who met DSM-III criteria (APA, 1980) for other diagnoses ('secondary depression'). The present study confirms and extends previous reports of hypothalamic-pituitary-adrenal axis hyperactivity in a large percentage of depressed patients as evidenced by lack of suppression of serum cortisol levels after orally administered dexamethasone. An abnormal DST was seen in 71% of patients with a DSM-III diagnosis of major depression. This was a significantly higher incidence when compared to patients with depressive symptoms with other DSM-III diagnoses (secondary depression).

UR - http://www.scopus.com/inward/record.url?scp=0020622649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020622649&partnerID=8YFLogxK

M3 - Article

C2 - 6860725

AN - SCOPUS:0020622649

VL - 18

SP - 505

EP - 511

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 4

ER -